Neoleukin Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch NLTX and buy or sell other stocks, ETFs, and their options commission-free!About NLTX
Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company was founded in May 2007 and is headquartered in New York, NY.
CEORachel L. McMinn, PhD
CEORachel L. McMinn, PhD
Employees107
Employees107
HeadquartersNew York, New York
HeadquartersNew York, New York
Founded2018
Founded2018
Employees107
Employees107
NLTX Key Statistics
Market cap444.59M
Market cap444.59M
Price-Earnings ratio-4.22
Price-Earnings ratio-4.22
Dividend yield—
Dividend yield—
Average volume186.53K
Average volume186.53K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$37.27
52 Week high$37.27
52 Week low$6.88
52 Week low$6.88
Stock Snapshot
Neoleukin Therapeutics(NLTX) stock is priced at $30.09, giving the company a market capitalization of 444.59M. It carries a P/E multiple of -4.22.
On 2026-01-09, Neoleukin Therapeutics(NLTX) shares started trading at —, with intraday highs of — and lows of —.
Trading activity shows a volume of 0, compared to an average daily volume of 186.53K.
The stock's 52-week range extends from a low of $6.88 to a high of $37.27.
The stock's 52-week range extends from a low of $6.88 to a high of $37.27.
People also own
Based on the portfolios of people who own NLTX. This list is generated using Robinhood data, and it’s not a recommendation.